SPACs increasingly are being used to take private biotech and health-care companies public, but they raise special due diligence issues because the companies are highly regulated and their products affect patients, Bloomberg reports, citing Reed Smith attorneys. They outline several key aspects that need extra scrutiny.
Due diligence for biotechnology companies is critical because they tend to be highly regulated by multiple government agencies, and the products can directly affect patients’ health and well-being. Without proper due diligence, latent problems could cause issues at any moment, putting the company and its investors’ funds at risk. Read more.
Related Posts
SoFi Nears $6B Deal with Social Capital Hedosophia V: Report
The deal would value SoFi at more than $6 billion and could be announced in the coming days, the sources said, cautioning that the talks could still collapse and the terms could be changed.
The Big Short (Squeeze)
Short-sellers aren't the only ones that lost money following a massive redemption in shares.
SPAC Dynamo Ellenoff Grossman & Schole Expands to CA: Report
New York-founded midsize firm Ellenoff Grossman & Schole has opened its first West Coast office, adding a pair of securities litigators in Irvine, California, Reuters reports.
SEC Fines JPMorgan Chase $10M for Improperly Deleting Records
JPMorgan declined to comment. The bank didn’t admit to or deny the regulator’s allegations.